Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ONA-255
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Reveal Genomics
Deal Size : Undisclosed
Deal Type : Collaboration
Reveal Genomics and Ona Therapeutics Partner to Advance Cancer Treatments
Details : The collaboration aims to accelerate the clinical development of ONA-255, a next-generation antibody-drug conjugate (ADC) designed to enhance the precision and effectiveness of cancer treatment.
Product Name : ONA-255
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
April 14, 2025
Lead Product(s) : ONA-255
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Reveal Genomics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Fund+
Deal Size : $33.6 million
Deal Type : Series A Financing
Fund+ Announces Investment in Ona Therapeutics EUR30 Million Series A Financing
Details : The financing will allow Ona Therapeutics to complete the pre-clinical development in a variety of tumor types and to move its lead candidate into first clinical studies in patients with metastatic cancer in 2023.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 16, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Fund+
Deal Size : $33.6 million
Deal Type : Series A Financing